Corrigendum to "Evaluation of 3-O-methyldopa as a biomarker for aromatic L-amino acid decarboxylase deficiency in 7 Brazilian cases" [27/100744/2021/ pages: 1-4].

[This corrects the article DOI: 10.1016/j.ymgmr.

Increased circulating levels of angiotensin-(1-7) in severely ill COVID-19 patients.

https://bit.ly/3xFXuTU.

Evaluation of 3--methyldopa as a biomarker for aromatic L-amino acid decarboxylase deficiency in 7 Brazilian cases.

Aromatic L-amino acid decarboxylase (AADCD) deficiency is an autosomal recessive neurometabolic disorder, caused by biallelic mutations in the gene, that impairs the synthesis or metabolism of neurotransmitters leading to severe motor dysfunction. The main clinical signs are oculogyric crisis, hypotonia, hypokinesia, and dystonia. The biochemical diagnosis can be performed in cerebrospinal fluid by neurotransmitter analysis, which requires an invasive lumbar puncture, and the sample needs to be shipped frozen to a reference laboratory, usually across a country border.